Neonmind’s NEO-002 artificial psilocybin candidate are going to be researched to be a reduced-dose cure to control and suppress patient urge for food. The company has secured pharmaceutical grade synthetic psilocybin from Psygen and anticipates initiating a Stage I/II proof-of-idea research for NEO-001 within the close to future. PharmaTher https://cassq110vqh4.blogchaat.com/profile